Description

Zolta (zoledronic acid) concentrate for solution for infusions 4 mg/5 ml. vial 5 ml. №1

Ingredients

Active ingredient: Zoledronic acid. Inactive ingredients may include mannitol, sodium citrate, and water for injection.

Dosage

Dosage: The usual dose is 4 mg infused over no less than 15 minutes every 6 months. Dosage adjustments may be needed based on renal function.

Indications

Indications: Zolta is indicated for the treatment and prevention of osteoporosis in postmenopausal women and in men at increased risk of fractures.

Contraindications

Contraindications: Zolta is contraindicated in patients with hypocalcemia and known hypersensitivity to zoledronic acid.

Directions

Administration: Zolta is administered as a slow intravenous infusion over at least 15 minutes. Adequate hydration should be maintained.

Scientific Evidence

Zoledronic acid, the active ingredient in Zolta, is a bisphosphonate that inhibits bone resorption. Studies have shown its efficacy in reducing the risk of fractures in osteoporotic patients. Research by Black et al. (2007) demonstrated a significant decrease in vertebral, nonvertebral, and hip fractures with zoledronic acid treatment.

Additional Information

Zolta has been shown to have a good safety profile with minimal side effects. Common side effects may include flu-like symptoms, fever, and bone pain. It is important to monitor renal function during treatment with Zolta.

Pharmacological Effects: Zoledronic acid works by inhibiting osteoclast activity, thereby reducing bone resorption and increasing bone mineral density. This helps in the prevention of fractures and improves bone strength.

Clinical Trials: Clinical trials have compared the effectiveness of Zolta with other bisphosphonates in the treatment of osteoporosis. A study by Cummings et al. (2009) showed that zoledronic acid was more effective in reducing the risk of fractures compared to alendronate.